|STUDIES 1 AND 21||
The primary efficacy variable in these trials was GH level.2,3
Secondary efficacy variables were IGF-1 levels and clinical symptoms and signs of acromegaly.2,3
1. Lancranjan I, Bruns C, Grass P, et al. Sandostatin® LAR®: A promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(8 suppl 1):67-71. 2. Lancranjan I, Atkinson AB; the Sandostatin® LAR® Group. Results of a European multicentre study with Sandostatin® LAR® in acromegalic patients. Pituitary. 1999;1(2):105-114. 3. Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab. 2003;88(7):3090-3098.
Please see the Summary of Product Characteristics.